• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Did Strong Q2 Earnings, Raised Guidance, and Cyber Recovery Just Shift Stryker's (SYK) Investment Narrative?

    Simply Wall St·08/01/2026 02:17:58
    Listen to the news
    • Stryker Corporation recently reported past second-quarter 2026 results, with sales rising to US$6.59 billion and net income to US$1.28 billion, lifting basic earnings per share from continuing operations to US$3.32.
    • Management’s decision to slightly raise full-year guidance, resume share repurchases, and highlight recovery from a March cyberattack underscores improving operational resilience and confidence in cash generation.
    • We’ll now explore how Stryker’s stronger earnings and raised guidance, alongside its cyber recovery, affect the existing investment narrative.

    Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

    Stryker Investment Narrative Recap

    Stryker appeals if you believe in long term growth in medical procedures, powered by its devices, robotics and global footprint. The latest quarter’s improved earnings, higher guidance and visible recovery from the cyberattack appear to support that view, while near term execution risk around supply chains and regulatory approvals remains largely unchanged for now.

    Among recent developments, the launch of the Mako RPS for Total Knee Replacement stands out in the context of catalysts tied to Stryker’s robotic assisted surgery platform. This expands the Mako ecosystem and may reinforce the company’s position in outpatient and minimally invasive orthopaedic procedures, which many investors already see as a key driver of demand for its broader portfolio.

    Yet, against this backdrop of improving results and product momentum, investors should also be aware of the risk that prolonged regulatory approvals in Europe could...

    Read the full narrative on Stryker (it's free!)

    Stryker's narrative projects $32.6 billion revenue and $6.5 billion earnings by 2029. This requires 8.9% yearly revenue growth and roughly a $3.2 billion earnings increase from $3.3 billion today.

    Uncover how Stryker's forecasts yield a $386.80 fair value, a 19% upside to its current price.

    Exploring Other Perspectives

    SYK 1-Year Stock Price Chart
    SYK 1-Year Stock Price Chart

    Seven fair value estimates from the Simply Wall St Community span roughly US$331 to US$425 per share, reflecting a wide band of expectations. When you weigh these views against Stryker’s growing focus on robotics and recent earnings momentum, it underlines why checking several perspectives on the company’s future performance can matter.

    Explore 7 other fair value estimates on Stryker - why the stock might be worth as much as 30% more than the current price!

    Decide For Yourself

    Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

    Seeking Other Investments?

    Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.